Protein-based nanotechnology: Antibody conjugated with photosensitizer in targeted anticancer photoimmunotherapy

International Journal of Oncology

Volumn 39, Issue 4, 2011, Pages 949-953

  Jankun, Jerzy ^a,b,c  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

CYT 351; Hematoporphyrin; LnCAP; Phototherapy

Indexed keywords

AVIDIN; HEMATOPORPHYRIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CYT 351; PHOTOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ARTICLE; CANCER IMMUNOTHERAPY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; HUMAN; HUMAN CELL; MINIMALLY INVASIVE PROCEDURE; NANOTECHNOLOGY; PHOTODYNAMIC THERAPY; PHOTOTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; GPI-LINKED PROTEINS; HEMATOPORPHYRINS; HUMANS; IMMUNOCONJUGATES; IMMUNOTHERAPY; LIGHT; MALE; MODELS, MOLECULAR; NANOTECHNOLOGY; NEOPLASM PROTEINS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROSTATIC NEOPLASMS;

EID: 79960866425     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1110     Document Type: Article

References (28)

1. Allison RR, Mota HC, Bagnato VS and Sibata CH: Bio-nanotechnology and photodynamic therapy - state of the art review. Photodiagnosis Photodyn Ther 5: 19-28, 2008. (Pubitemid 351337662)
2. Jankun J, Keck RW, Skrzypczak-Jankun E, Lilge L and Selman SH: Diverse optical characteristic of the prostate and light delivery system: implications for computer modelling of prostatic photodynamic therapy. BJU Int 95: 1237-1244, 2005. (Pubitemid 40799437)
3. Mitton D and Ackroyd R: A brief overview of photodynamic therapy in Europe. Photodiagnosis Photodyn Ther 5: 103-111, 2008.
4. Jankun J, Lilge L, Douplik A, et al: Optical characteristics of the canine prostate at 665 nm sensitized with tin etiopurpurin dichloride: need for real-time monitoring of photodynamic therapy. J Urol 172: 739-743, 2004. (Pubitemid 38900252)
5. Mew D, Lum V, Wat CK, et al: Ability of specific monoclonal antibodies and conventional antisera conjugated to hematoporphyrin to label and kill selected cell lines subsequent to light activation. Cancer Res 45: 4380-4386, 1985. (Pubitemid 16224901)
6. Mew D, Wat CK, Towers GH and Levy JG: Photoimmunotherapy: treatment of animal tumors with tumor-specific monoclonal antibody-hematoporphyrin conjugates. J Immunol 130: 1473-1477, 1983. (Pubitemid 13159902)
7. Novichenko NL, Mamchur AA, Lisniak IO and Gamaliya MF: Study of photodynamic efficiency of the hematoporphyrin conjugated with antibody to VEGF in mouse Lewis carcinoma. Exp Oncol 30: 315-318, 2008.
8. Allen TM and Cullis PR: Drug delivery systems: entering the mainstream. Science 303: 1818-1822, 2004. (Pubitemid 38374867)
9. Stalteri MA, Mather SJ, Belinka BA, Coughlin DJ, Chengazi VU and Britton KE: Site-specific conjugation and labelling of prostate antibody 7E11C5.3 (CYT-351) with technetium-99m. Eur J Nucl Med 24: 651-654, 1997. (Pubitemid 27299745)
10. Van Dongen GA, Visser GW and Vrouenraets MB: Photosensitizer-antibody conjugates for detection and therapy of cancer. Adv Drug Deliv Rev 56: 31-52, 2004. (Pubitemid 38045423)
11. Novick S, Quastel MR, Marcus S, et al: Linkage of boronated polylysine to glycoside moieties of polyclonal antibody; boronated antibodies as potential delivery agents for neutron capture therapy. Nucl Med Biol 29: 159-167, 2002. (Pubitemid 34127948)
12. O'Shannessy DJ, Dobersen MJ and Quarles RH: A novel procedure for labeling immunoglobulins by conjugation to oligosaccharide moieties. Immunol Lett 8: 273-277, 1984. (Pubitemid 15207051)
13. O'Shannessy DJ and Quarles RH: Specific conjugation reactions of the oligosaccharide moieties of immunoglobulins. J Appl Biochem 7: 347-355, 1985. (Pubitemid 16130699)
14. Liu T, Wu LY and Berkman CE: Prostate-specific membrane antigen-targeted photodynamic therapy induces rapid cytoskeletal disruption. Cancer Lett 296: 106-112, 2010.
15. Kwitniewski M, Juzeniene A, Glosnicka R and Moan J: Immunotherapy: a way to improve the therapeutic outcome of photodynamic therapy? Photochem Photobiol Sci 7: 1011-1017, 2008.
16. Milgrom LR: Towards recombinant antibody-fragment targeted photodynamic therapy. Sci Prog 91: 241-263, 2008.
17. Nowak-Sliwinska P, van Beijnum JR, van Berkel M, van den Bergh H and Griffioen AW: Vascular regrowth following photodynamic therapy in the chicken embryo chorioallantoic membrane. Angiogenesis 13: 281-292, 2010.
18. Bellnier DA, Greco WR, Loewen GM, Nava H, Oseroff AR and Dougherty TJ: Clinical pharmacokinetics of the PDT photosensitizers porfimer sodium (Photofrin), 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (Photochlor) and 5-ALA-induced protoporphyrin IX. Lasers Surg Med 38: 439-444, 2006.
19. Brasseur N, Ouellet R, Lewis K, Potter WR and van Lier JE: Photodynamic activities and skin photosensitivity of the bis (dimethylthexylsiloxy)silicon 2,3-naphthalocyanine in mice. Photochem Photobiol 62: 1058-1065, 1995. (Pubitemid 3019998)
20. Kostron H: Photodynamic diagnosis and therapy and the brain. Methods Mol Biol 635: 261-280, 2010.
21. Kostron H, Obwegeser A and Jakober R: Photodynamic therapy in neurosurgery: a review. J Photochem Photobiol B 36: 157-168, 1996. (Pubitemid 27011261)
22. Roberts WG, Smith KM, McCullough JL and Berns MW: Skin photosensitivity and photodestruction of several potential photodynamic sensitizers. Photochem Photobiol 49: 431-438, 1989.
23. Hornick JL, Khawli LA, Hu P, Sharifi J, Khanna C and Epstein AL: Pretreatment with a monoclonal antibody/interleukin-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumors. Clin Cancer Res 5: 51-60, 1999. (Pubitemid 29045177)
24. Chang SS: Overview of prostate-specific membrane antigen. Rev Urol 6 (Suppl 10): S13-S18, 2004.
25. Horoszewicz JS, Kawinski E and Murphy GP: Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 7: 927-935, 1987. (Pubitemid 18036141)
26. Troyer JK, Feng Q, Beckett ML and Wright GL Jr: Biochemical characterization and mapping of the 7E11-C5.3 epitope of the prostate-specific membrane antigen. Urol Oncol 1: 29-37, 1995.
27. Vallabhajosula S, Smith-Jones PM, Navarro V, Goldsmith SJ and Bander NH: Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice. Prostate 58: 145-155, 2004. (Pubitemid 38160901)
28. Liu T, Wu LY, Choi JK and Berkman CE: In vitro targeted photodynamic therapy with a pyropheophorbide-a conjugated inhibitor of prostate-specific membrane antigen. Prostate 69: 585-594, 2009.